Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low-Risk TAVR Trial Shows Low Mortality at 1 Year

Key clinical point: Anticipating pivotal trials due next week at ACC, investigator-led study shows excellent TAVR results in low risk patients.

Major finding: At one year, cardiovascular-related mortality was 1% and there were no disabling strokes.

Data Source: Investigator-led non-randomized study.

Disclosures: Dr. Waksman reports financial relationships with numerous manufacturers of devices for interventional cardiology including those that produce TAVR devices.

Citation:

2019 Cardiovascular Research Technologies.